Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Mini-hormone fights iron

Iron overload commonly leads to organ damage and even death. Currently available treatments for iron overload are burdensome or cause side effects.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Press release: 18th Congress of the European Hematology Association in Stockholm, Sweden June 13-16-2013

The EHA-theme of the year, from June 2013 to June 2014, is dedicated to “Age and Aging in blood disorders”.

Read more

Press release: Work of 2013 Nobel Prize in Physiology or Medicine winners to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

With the Scientific Working Group for Stem Cells, the 18th Congress of EHA took the opportunity to acknowledge the work of the 2013 winner of the Nobel Prize for Medicine or Physiology, Drs John B.

Read more

Press Release: News on Red Cells and Iron presented at the 18th Congress of the European Hematology Asscociation in Stockholm June 13-16, 2013

Recent evidence suggests that these congenital anaemias are caused by molecular abnormalities in the transport of iron and other molecules and a deeper understanding of these mechanisms may lead to a better knowledge of the normal development of the red…

Read more

Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013

In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.

Read more

EU commissioner Tonio Borg: 'we will continue to improve the life of people suffering from Thalassaemia'

 

Today, May 8, is International Thalassemia Day. Today, we seek to enhance the awareness and knowledge of thalassemia and other hemoglobin disorders.

Read more